Tweet
Effectiveness of autologous bone marrow mesenchymal stem cells intrathecal transplantation in patients with secondary progressive multiple sclerosis
M. Swiderek-Matysiak1, J. Wojtkiewicz2, A. Habich2, I. Selmaj1, W. Maksymowicz2, K. Selmaj1 1Medical University of Lodz, Department of Neurology, Lodz, 2University of Warmia and Mazury, Department of Neurosurgery, Olsztyn, Poland
Objective: To assess safety and therapeutic benefit of intrathecal administration of autologous mesenchymal stem cells (MSCs) in patients with secondary progressive multiple sclerosis (MS) who failed on previous therapies.
Methods: Twelve MS patients with disability progression by 1.0 point in the EDSS (Expanded Disability Status Scale) in past 12 months were included in the study. Mean EDSS score at baseline was 7.33 point, disease duration 9 to 20 years. Mean patients age was 48,1 years and gender ratio female/male 5/7. MSCs (CD 73, CD 90, CD 105 positive) were isolated from bone marrow and cultured for 4-5 weeks. After four passages, 20-25x106 of fresh MSCs were injected in single intrathecal infusion. Patients underwent a neurological assessment at baseline, 3, 6 and 12 months post-injection including EDSS, MSFC (Multiple Sclerosis Functional Composite) and SDMT (Symbol Digit Modalities Test).
Results: Six patients had injection-related adverse events of mild intensity (headache, backache). No major adverse effects were reported during 12 months of study follow-up. The mean EDSS improved during 1 year of follow-up by 0,25. At the end of 12 month follow-up, the EDSS score remained unchanged in 6 patients and was reduced by 0.5 degree in the other 6 patients compare to baseline. Cognitive function in SDMT was tested in 9 patients and showed improvement in 6, stabilization in 2 and worsening in 1 patient.
Conclusion: Intrathecal administration of autologous MSCs in patients with secondary progressive multiple sclerosis was safe well tolerated procedure and showed modest clinical benefit.
M. Swiderek-Matysiak1, J. Wojtkiewicz2, A. Habich2, I. Selmaj1, W. Maksymowicz2, K. Selmaj1 1Medical University of Lodz, Department of Neurology, Lodz, 2University of Warmia and Mazury, Department of Neurosurgery, Olsztyn, Poland
Objective: To assess safety and therapeutic benefit of intrathecal administration of autologous mesenchymal stem cells (MSCs) in patients with secondary progressive multiple sclerosis (MS) who failed on previous therapies.
Methods: Twelve MS patients with disability progression by 1.0 point in the EDSS (Expanded Disability Status Scale) in past 12 months were included in the study. Mean EDSS score at baseline was 7.33 point, disease duration 9 to 20 years. Mean patients age was 48,1 years and gender ratio female/male 5/7. MSCs (CD 73, CD 90, CD 105 positive) were isolated from bone marrow and cultured for 4-5 weeks. After four passages, 20-25x106 of fresh MSCs were injected in single intrathecal infusion. Patients underwent a neurological assessment at baseline, 3, 6 and 12 months post-injection including EDSS, MSFC (Multiple Sclerosis Functional Composite) and SDMT (Symbol Digit Modalities Test).
Results: Six patients had injection-related adverse events of mild intensity (headache, backache). No major adverse effects were reported during 12 months of study follow-up. The mean EDSS improved during 1 year of follow-up by 0,25. At the end of 12 month follow-up, the EDSS score remained unchanged in 6 patients and was reduced by 0.5 degree in the other 6 patients compare to baseline. Cognitive function in SDMT was tested in 9 patients and showed improvement in 6, stabilization in 2 and worsening in 1 patient.
Conclusion: Intrathecal administration of autologous MSCs in patients with secondary progressive multiple sclerosis was safe well tolerated procedure and showed modest clinical benefit.